BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 38690101)

  • 1. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary lung adenocarcinoma with breast metastasis harboring the EML4‑ALK fusion: A case report.
    Zhang W; Zhang Y; Zhou L; Tan N; Bai Y; Xing S
    Oncol Lett; 2024 Jun; 27(6):276. PubMed ID: 38690101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W; Liang J; Zhang D; Huang X; Lv Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
    Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
    Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
    Xu X; Liu D; Wen J; Chen J; Fan M
    Transl Lung Cancer Res; 2020 Dec; 9(6):2500-2507. PubMed ID: 33489810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
    Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK fusions in the pan-cancer setting: another tumor-agnostic target?
    Shreenivas A; Janku F; Gouda MA; Chen HZ; George B; Kato S; Kurzrock R
    NPJ Precis Oncol; 2023 Sep; 7(1):101. PubMed ID: 37773318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancer with breast metastasis: a case report and review of the literature.
    Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
    J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer statistics, 2023.
    Siegel RL; Miller KD; Wagle NS; Jemal A
    CA Cancer J Clin; 2023 Jan; 73(1):17-48. PubMed ID: 36633525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer.
    Cocks K; Wells JR; Johnson C; Schmidt H; Koller M; Oerlemans S; Velikova G; Pinto M; Tomaszewski KA; Aaronson NK; Exall E; Finbow C; Fitzsimmons D; Grant L; Groenvold M; Tolley C; Wheelwright S; Bottomley A;
    Eur J Cancer; 2023 Jan; 178():128-138. PubMed ID: 36436330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry and Immunofluorescence.
    Hussaini HM; Seo B; Rich AM
    Methods Mol Biol; 2023; 2588():439-450. PubMed ID: 36418703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
    Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
    Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EML4-ALK fusion gene in non-small cell lung cancer.
    Lei Y; Lei Y; Shi X; Wang J
    Oncol Lett; 2022 Aug; 24(2):277. PubMed ID: 35928804
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.